Cramer Rosenthal Mcglynn LLC trimmed its position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 3.0% during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 174,005 shares of the medical research company’s stock after selling 5,385 shares during the period. Bio-Rad Laboratories accounts for 1.5% of Cramer Rosenthal Mcglynn LLC’s investment portfolio, making the stock its 19th biggest holding. Cramer Rosenthal Mcglynn LLC owned 0.58% of Bio-Rad Laboratories worth $54,392,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. BB&T Corp grew its position in Bio-Rad Laboratories by 3.2% during the 2nd quarter. BB&T Corp now owns 1,503 shares of the medical research company’s stock worth $469,000 after purchasing an additional 47 shares in the last quarter. Municipal Employees Retirement System of Michigan boosted its stake in shares of Bio-Rad Laboratories by 1.4% during the 2nd quarter. Municipal Employees Retirement System of Michigan now owns 3,720 shares of the medical research company’s stock valued at $1,163,000 after buying an additional 50 shares during the period. Farr Miller & Washington LLC DC boosted its stake in shares of Bio-Rad Laboratories by 2.9% during the 2nd quarter. Farr Miller & Washington LLC DC now owns 1,925 shares of the medical research company’s stock valued at $602,000 after buying an additional 54 shares during the period. Commerce Bank boosted its stake in shares of Bio-Rad Laboratories by 7.1% during the 2nd quarter. Commerce Bank now owns 873 shares of the medical research company’s stock valued at $273,000 after buying an additional 58 shares during the period. Finally, Advisory Services Network LLC boosted its stake in shares of Bio-Rad Laboratories by 64.9% during the 2nd quarter. Advisory Services Network LLC now owns 160 shares of the medical research company’s stock valued at $50,000 after buying an additional 63 shares during the period. Hedge funds and other institutional investors own 62.46% of the company’s stock.
A number of equities research analysts have issued reports on the stock. Barclays lifted their target price on shares of Bio-Rad Laboratories from $350.00 to $380.00 and gave the company an “overweight” rating in a research note on Friday, August 2nd. They noted that the move was a valuation call. Goldman Sachs Group raised shares of Bio-Rad Laboratories from a “buy” rating to a “conviction-buy” rating and set a $400.00 target price for the company in a research note on Tuesday, August 20th. Finally, ValuEngine lowered shares of Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research note on Tuesday. Three analysts have rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $378.33.
Shares of BIO stock traded up $1.95 on Friday, hitting $337.84. The company’s stock had a trading volume of 10,955 shares, compared to its average volume of 200,153. The company has a debt-to-equity ratio of 0.11, a current ratio of 4.68 and a quick ratio of 3.36. Bio-Rad Laboratories, Inc. has a fifty-two week low of $220.05 and a fifty-two week high of $345.50. The firm’s fifty day moving average price is $329.75 and its 200-day moving average price is $309.28. The stock has a market capitalization of $9.62 billion, a price-to-earnings ratio of 57.85, a P/E/G ratio of 2.99 and a beta of 1.18.
Bio-Rad Laboratories (NYSE:BIO) last released its quarterly earnings data on Thursday, August 1st. The medical research company reported $1.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.39 by $0.18. The business had revenue of $572.60 million during the quarter, compared to analyst estimates of $564.88 million. Bio-Rad Laboratories had a net margin of 39.32% and a return on equity of 3.92%. Bio-Rad Laboratories’s quarterly revenue was down .6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.64 EPS. Analysts predict that Bio-Rad Laboratories, Inc. will post 7.19 EPS for the current fiscal year.
Bio-Rad Laboratories Company Profile
Bio-Rad Laboratories, Inc develops, manufactures, and markets products and solutions for the life science research and clinical diagnostic markets in Europe, the Pacific Rim, the United States, and internationally. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components.
Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.